BioSpace News Archive

In a shining moment that signaled hope for hemophilia B patients, uniQure presented data on Tuesday showing that its gene therapy treatment, etranacogene dezaparvovec (AMT-061), substantially increased production of the blood-clotting protein factor IX in nearly all pivotal Phase III HOPE-B trial participants.

As the year wraps up, there are still some PDUFA dates on the agency’s calendar. Read on for this week’s.

Augmented adoption of face masks as a tool of precaution to safeguard oneself from different diseases, such Ebola, swine flu, avian bird flu, influenza, Covid-19, and anthrax has played an important role in the development of the global reusable face mask market.

Virtual Clinical Trials (VCTs), also called remote or decentralized trials, are a comparatively new and yet underutilized method of conducting clinical research taking full advantage of technologies such as apps, electronic monitoring devices, and online social engagement platforms

The healthcare mobility solutions market is anticipated to witness a significant growth in the upcoming years on account of the increasing adoption of mobile clinical systems and accessibility of critical business.

Exosomes possesses the potential to be a carrier for drug delivery owing to their transportation properties.

Recombinant protein is a manipulated form of protein, which is generated in various ways to produce large quantities of proteins, modify gene sequences, and manufacture useful commercial products. The formation of recombinant protein is carried out in specialized vehicles known as vectors.

Increase in the number of kaposi sarcoma patients in all worldwide locations is likely to fuel the growth of the global kaposi sarcoma diagnosis market during the assessment period of 2020 to 2030.

The global rare disease gene therapy is expected to witness a significant growth in the forecast period, 2020-2030 on account of the increasing cases of genetic diseases worldwide.

Polyphor AG announced the extension of its existing grant agreement with CARB-X, a global partnership led by Boston University dedicated to supporting the development of antibacterial products to diagnose, prevent and treat drug-resistant infections.